Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipients.
BACKGROUND
Invasive aspergillosis is a major cause of morbidity and mortality in lung transplant recipients (LTR), occurring in up to 15% of patients post-transplant. The 14% aspergillus incidence at the Cleveland Clinic Foundation prompted institution of universal prophylaxis with oral itraconazole (ICZ) in 1997. We report our experience with two protocols of ICZ administration in non-cystic fibrosis LTR and the interaction with cyclosporine (CSA).


METHODS
Group 1 patients (n=12) were administered ICZ capsules in a fasting or fed state, with or without a histamine-2 (H-2) receptor antagonist or proton pump inhibitor. Group 2 patients (n=12) received the same protocol as group I, but in a fed state with a carbonated beverage (cola) to increase acidity in the stomach to enhance absorption of ICZ. The ICZ dose was 200 mg/d, given as one daily dose. A historical control group (n=10) did not receive chemoprophylaxis with ICZ. CSA daily doses, dose intervals, concentration, cost, and random ICZ levels were documented over a 4-month period of time and compared using generalized estimating equations.


RESULTS
The daily CSA mg/kg/d dose decreased over time in all three groups, but no differences were found between the three groups. The CSA dosing interval over time was significantly prolonged in group 2 compared to group 1 or the control group (p< or =0.003). Over time, there was no difference in CSA concentration between all groups. There was no difference in cost over time between the three groups; however, the mean cost of CSA therapy was significantly lower in group 2 compared to the control group (p=0.025). Group 2 administered ICZ with cola had greater random blood concentrations of ICZ (p=0.019).


CONCLUSIONS
ICZ capsules administered in a fed state with a cola resulted in greater random levels of ICZ, a decrease in cost/d of CSA, and a prolongation of CSA dosing interval. Although daily CSA dosage trended lower in group 2, it did not reach statistical significance. We believe these changes in CSA dosing over time reflect increased absorption of ICZ and recommend verifying ICZ absorption with an itraconazole level, especially when CSA intervals are not prolonged.
Department of Pharmacy, Loyola University Medical Center, Maywood, IL, USA.
S L
SL
Wimberley
M T
MT
Haug
K M
KM
Shermock
A
A
Qu
J R
JR
Maurer
A C
AC
Mehta
R J
RJ
Schilz
S M
SM
Gordon
D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001228:Aspergillosis / Q000517:prevention & control; D002253:Carbonated Beverages; D016572:Cyclosporine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004347:Drug Interactions; D018565:Food-Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D017964:Itraconazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008172:Lung Diseases, Fungal / Q000517:prevention & control; D016040:Lung Transplantation; D009894:Opportunistic Infections / Q000517:prevention & control; D012189:Retrospective Studies
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D017964:Itraconazole; D016572:Cyclosporine